Overweight and the use of psychiatric drugs in patients with mental disorders attended at psychosocial care center, Teresina, Piauí, Brazil.
Psychopharmacology brought numerous benefits to people with mental disorders, although undesirable side effects have arisen, including weight gain. Identify the overweight frequency in individuals with mental disorders and its relation with the use of psychiatric drugs. Cross-sectional study with patients with mental disorders of both sexes, older than 18 years. Body Mass Index (BMI) used to diagnose overweight (BMI > 25 kg/m2). Chi-square test of Pearson (c²) and Poisson regression were used for analytical statistics for association between variables. the study involved 109 individuals. Overweight was found in 70.7% of the study population, 29.4% presented pre-obesity, 26.6% were obese class I, 8.3%, obese class II, and 6.4% obese grade III (morbid). The overweight prevalence was significantly higher among patients who used selective serotonin reuptake inhibitor antidepressants (PR = 1,42, 95% CI 1,12 to 1,80, p = 0,004), typical antipsychotics (PR = 1,43, 95% CI 1,13 to 1,80, p = 0,003), atypical antipsychotics (PR = 1,24, 95% CI 1,01 to 1,54, p = 0,045) and benzodiazepines (PR = 1,37, 95% CI 1,10 to 1,71, p = 0,004) when compared to those who used tricycle antidepressants ((PR=1,20, 95% CI 0,93 to 1,54, p=0,153) and mood stabilizers (PR=1,09, 95% IC 0,88 to 1,35, p=0,416) . High prevalence of overweight significantly higher among patients who used selective serotonin reuptake inhibitor antidepressants, typical and atypical antipsychotics and benzodiazepines.